Welcome to LookChem.com Sign In|Join Free
  • or
(2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide, also known as CP-10, is a thiazole derivative featuring a cyclopentyl group and a methanesulfonylphenyl group. It is a potent and selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH), which is involved in the endocannabinoid system. CP-10 has been investigated for its potential therapeutic effects in pain relief and inflammation, although further research is required to fully elucidate its pharmacological properties and potential applications.

300353-13-3

Post Buying Request

300353-13-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

300353-13-3 Usage

Uses

Used in Pharmaceutical Industry:
(2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide is used as a therapeutic agent for pain relief and inflammation management due to its ability to inhibit the FAAH enzyme, thereby modulating the endocannabinoid system and potentially providing analgesic and anti-inflammatory effects.
Used in Research Applications:
In the field of scientific research, (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide serves as a valuable tool compound for studying the role of the FAAH enzyme and the endocannabinoid system in various physiological and pathological processes. This helps in advancing our understanding of these systems and may contribute to the development of new therapeutic strategies for related conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 300353-13-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,0,3,5 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 300353-13:
(8*3)+(7*0)+(6*0)+(5*3)+(4*5)+(3*3)+(2*1)+(1*3)=73
73 % 10 = 3
So 300353-13-3 is a valid CAS Registry Number.

300353-13-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name (2R)-3-Cyclopentyl-2-[4-(methanesulfonyl)phenyl]-N-(thiazol-2-yl)propionamide

1.2 Other means of identification

Product number -
Other names Ro 28-1675

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:300353-13-3 SDS

300353-13-3Downstream Products

300353-13-3Relevant academic research and scientific papers

Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2 R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N- thiazol-2-yl-propionamide (RO0281675)

Haynes, Nancy-Ellen,Corbett, Wendy L.,Bizzarro, Fred T.,Guertin, Kevin R.,Hilliard, Darryl W.,Holland, George W.,Kester, Robert F.,Mahaney, Paige E.,Qi, Lida,Spence, Cheryl L.,Tengi, John,Dvorozniak, Mark T.,Railkar, Aruna,Matschinsky, Franz M.,Grippo, Joseph F.,Grimsby, Joseph,Sarabu, Ramakanth

supporting information; experimental part, p. 3618 - 3625 (2010/07/05)

Glucokinase (GK) is a glucose sensor that couples glucose metabolism to insulin release. The important role of GK in maintaining glucose homeostasis is illustrated in patients with GK mutations. In this publication, identification of the hit molecule 1 and its SAR development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described. Compound 21a (RO0281675) was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.

SUBSTITUTED (THIAZOL-2-YL) -AMIDE OR SULFONAMIDE AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES

-

Page 32, (2010/02/07)

Compounds of the formula (I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention and treatm

Heteroaromatic glucokinase activators

-

, (2008/06/13)

2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 2-position being a substituted phenyl group and at the 3-position being a cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 300353-13-3